This would also have bearing for other combination regimens, eg the BEACON regimen of using the anti-EGFR agent with a BRAFV600E-inhibitor for patients with colorectal cancer.8 Broad knowledge and adoption of less frequent dosing would be something that would be well received by oncologists, as well as patients and caregivers alike. This evidence concerns the gene EGFR and colorectal cancer.